NelsonW, Bagley S, Watt CD, and Nasrallah M: An institutional experience with pyrosequencing for MGMT promoter methylation analysis. Modern Pathology 32 (supplement 2): 29,2019.
Belman J, Gentile C, Lake JI, Roth JJ and Watt CD: Optimizing RNA extraction to facilitate BCR/ABL1 quantitative testing. The Journal of Molecular Diagnostics 20 (6): 1031,2018.
Bhattacharyya S, Castro-Echeverry E, Kelly LM, Burnes CL, Gentile C, Roy S, Nikiforova M, Watt CD and Aggarwal N: Standardization of FLT3-ITD mutation allelic ratio reporting in the clinical laboratory setting. The Journal of Molecular Diagnostics 20 (6): 920,2018.
Rathore S, Bakas S, Nasrallah MP, Bagley SJ, Akbari H, Ha SM, Mamourian EC, Watt CD, and Davatzikos C: Non-invasive determination of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status in glioblastoma (GBM) using magnetic resonance imaging (MRI). Journal of Clinical Oncology 36 (suppl): 2018.
McMahon CM, Ferng TT, Canaani J, Rea B, Sargent RL, Morrissette JJD, Lieberman DB, Watt CD, Durruthy-Durruthy R, Pellegrino M, Eastburn DJ, Wang ES, Shah NP, Carroll M, Smith CC, and Perl AE: Ras mutations are the dominant mechanism of secondary resistance to gilteritinib therapy for relapsed/refractory FLT3-mutated AML. EHA Learning Center : 2018.
McMahon CM, Canaani J, Rea B, Sargent RL, Morrissette JJD, Lieberman DB, Watt CD, Schwartz GW, Faryabi RB, Ferng TT, Shah NP, Smith CC, Caroll M, and Perl AE: Mechanisms of acquired resistance to Gilteritinib therapy in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood 130 (s1): 295,2017.
Hatem J, Schrank-Hacker AM, Watt CD, Morrissette JJ, Rubin AI, Kim EJ, Nasta SD, Wasik MA, Bogusz AM.: Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report. Diagnostic Pathology 11 : 137,2016.
Surrey LF, Smith JR, Lubin D, Van Deerlin V, Watt CD: Analytic Approach for Complete and Mixed Engraftment Analysis using Commercial Software. The Journal of Molecular Diagnostics 18 (6): 1030,2016.
Press RD, Watt CD, Cai L, Van Deerlin VM, Roth JJ, Gentile C, Loren A, and Eickelberg G: BCR-ABL1 molecular responses at 12-18 months predict long-term event-free survival in patients with tyrosine kinase inhibitor (TKI)-treated chronic myelogenous leukemia (CML). The Journal of Molecular Diagnostics 18 (6): 964,2016.
Roth JJ, Windon AL, Strubinger J, Carlin A, Gentile C, Watt CD, McGrath CM, Van Deerlin VM: Improvements in workflow after verification and implementation of the cobas® HPV Test. The Journal of Molecular Diagnostics 18 (6): 970,2016.